• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Reports First Quarter 2025 Financial Results

    5/7/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    •  Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1%
    • Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds
    • Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance:
      • Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2%
      • Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy

    Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025.

    Frank H. Laukien, Bruker's President and CEO, commented: "Bruker had a solid start to 2025 with double-digit reported and CER revenue growth, 5.1% organic revenue growth in our BSI segment, and better operating margin performance than expected - all on strong execution, despite uncertainties in key markets. In Q1 and April, we launched key products in spatial biology, NMR, microbiology and molecular diagnostics. Proactive cost management helped drive organic operating margin expansion, partially offsetting the expected Q1 margin headwinds from our strategic acquisitions in Q2 of 2024."

    He continued: "It has become evident that academic market and tariff dynamics will have a meaningful impact on our financial performance in 2025, and accordingly we are lowering our organic revenue growth and non-GAAP EPS guidance for the full year. With additional cost and pricing initiatives, as well as supply network re-engineering, we anticipate that we will be able to mitigate slightly more than half of the new headwinds in 2025. We expect to resume our planned margin expansion and rapid EPS growth in 2026 and beyond."

    First Quarter 2025 Financial Results

    Bruker's revenues for the first quarter of 2025 were $801.4 million, an increase of 11.0% compared to $721.7 million in the first quarter of 2024. In the first quarter of 2025, revenues increased 2.9% organically year-over-year, with constant-exchange rate (CER) revenue growth of 12.5%. Revenue growth from acquisitions was 9.6%, while foreign currency translation had an unfavorable impact of 1.5%.

    First quarter 2025 Bruker Scientific Instruments (BSI) revenues of $744.5 million increased 14.3% year-over-year, with organic revenue growth of 5.1%. First quarter 2025 Bruker Energy & Supercon Technologies (BEST) revenues of $59.3 million decreased 18.9% year-over-year, with organic revenue, net of intercompany eliminations, decreasing by 17.7%.

    First quarter 2025 GAAP operating income was $31.8 million, compared to $64.8 million in the first quarter of 2024. Non-GAAP operating income was $101.7 million in the first quarter of 2025, compared to $100.7 million in the first quarter of 2024. Bruker's first quarter 2025 non-GAAP operating margin was 12.7%, compared to 14.0% in the first quarter of 2024, primarily due to expected margin headwinds from our strategic acquisitions in the second quarter of 2024.

    First quarter 2025 GAAP diluted earnings per share (EPS) were $0.11, compared to $0.35 in the first quarter of 2024. First quarter 2025 non-GAAP diluted EPS were $0.47, a decrease of 11.3% compared to $0.53 in the first quarter of 2024.

    Updated Fiscal Year 2025 Financial Outlook

    Bruker now expects FY 2025 revenues of $3.48 to $3.55 billion, compared to FY 2024 revenues of $3.37 billion, with 3.5% to 5.5% year-over-year reported revenue growth, including:

    • CER revenue growth of 2.5% to 4.5%
    • Organic revenue growth of 0% to 2%
    • M&A revenue growth contribution of ~2.5%
    • Foreign currency translation revenue tailwind of ~1%

    Bruker now expects FY 2025 non-GAAP EPS of $2.40 to $2.48, compared to FY 2024 non-GAAP EPS of $2.41, which implies growth of 0% to 3% year-over-year, with CER non-GAAP EPS growth of 5% to 8%.

    Bruker's FY 2025 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates and tariff rates as of April 30, 2025.

    For the Company's outlook for 2025 organic revenue growth, M&A revenue growth, constant exchange rate revenue growth, and constant exchange rate non-GAAP EPS growth, and non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see "Use of Non-GAAP Financial Measures" below for a description of items excluded from our expected non-GAAP EPS.

    Quarterly Earnings Call

    Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 7, 2025, at 8:30 am Eastern Time. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2025 Earnings Webcast" hyperlink. A slide presentation will be referenced during the webcast and will be posted to our Investor Relations website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing "Bruker's First Quarter 2025 Earnings Conference Call".

    Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10198987/fef65dcb43 and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call.

    A telephone replay of the conference call will be available by dialing 1-877-344-7529 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 1883665. The replay will be available beginning one hour after the end of the conference call through June 7, 2025.

    About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR)

    Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

    Use of Non-GAAP Financial Measures

    To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating income margin; non-GAAP SG&A expense; non-GAAP interest and other income (expense), net; non-GAAP profit before income taxes; non-GAAP income tax rate; non-GAAP net income and non-GAAP diluted earnings per share. These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, and other non-operational costs.

    We also may refer to constant-exchange rate (CER) currency revenue growth, constant-exchange rate (CER) Non-GAAP EPS growth, and free cash flow or use which are also non-GAAP financial measures. We define the term CER currency revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates. We define the term CER EPS as Non-GAAP EPS excluding the effect of changes in foreign currency translation rates. We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders.

    The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. However, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

    We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.

    Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements.

    With respect to our outlook for 2025 non-GAAP organic revenue, non-GAAP M&A revenue, non-GAAP constant exchange rate (CER) revenue and non-GAAP EPS, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management's control and could significantly impact, either individually or in the aggregate, our future period revenues and EPS presented in accordance with GAAP.

    Forward-Looking Statements

    Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2025 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER Non-GAAP EPS growth; effects of academic market and tariff dynamics on our future financial results and our ability to mitigate such effects in the future; management's expectations for the impact of foreign currency and acquisitions; and for future financial and operational performance and business outlook; future economic conditions; and statements found under the "Use of Non-GAAP Financial Measures" section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, the length and severity of any recession and the impact on global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from its ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, the conflict in Israel, Palestine and surrounding areas and the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, continued volatility in the capital markets, the impact of increased interest rates, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, including our recent acquisitions of PhenomeX, ELITech, Chemspeed, and NanoString, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, the impact of foreign currency exchange rates, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2024, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

    Bruker Corporation

    PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

    (in millions)

     

     

    March 31,

    2025

     

    December 31,

    2024

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    184.2

     

    $

    183.4

    Accounts receivable, net

     

    537.8

     

     

    565.5

    Inventories

     

    1,116.5

     

     

    1,067.8

    Other current assets

     

    273.0

     

     

    236.5

    Total current assets

     

    2,111.5

     

     

    2,053.2

    Property, plant and equipment, net

     

    689.0

     

     

    669.3

    Goodwill, intangibles, net and other long-term assets

     

    3,132.6

     

     

    3,084.2

    Total assets

    $

    5,933.1

     

    $

    5,806.7

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND

    SHAREHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt and finance lease obligations

    $

    37.7

     

    $

    32.5

    Accounts payable

     

    244.6

     

     

    234.1

    Deferred revenue and customer advances

     

    470.6

     

     

    438.2

    Other current liabilities

     

    592.0

     

     

    576.5

    Total current liabilities

     

    1,344.9

     

     

    1,281.3

    Long-term debt

     

    2,076.1

     

     

    2,061.8

    Other long-term liabilities

     

    660.9

     

     

    648.4

     

     

     

     

    Redeemable noncontrolling interests

     

    18.3

     

     

    18.1

     

     

     

     

    Total shareholders' equity

     

    1,832.9

     

     

    1,797.1

    Total liabilities, redeemable noncontrolling interests and shareholders' equity

    $

    5,933.1

     

    $

    5,806.7

    Bruker Corporation

    PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

    (in millions, except per share data)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Revenue

    $

    801.4

     

     

    $

    721.7

    Cost of revenue

     

    410.2

     

     

     

    368.9

    Gross profit

     

    391.2

     

     

     

    352.8

    Operating expenses:

     

     

     

     

    Selling, general and administrative

     

    225.4

     

     

     

    195.3

    Research and development

     

    97.1

     

     

     

    81.8

    Other charges, net

     

    36.9

     

     

     

    10.9

    Total operating expenses

     

    359.4

     

     

     

    288.0

    Operating income

     

    31.8

     

     

     

    64.8

    Interest and other income (expense), net

     

    (6.7

    )

     

     

    6.8

    Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries (a)

     

    25.1

     

     

     

    71.6

    Income tax provision

     

    8.7

     

     

     

    19.8

    Equity in income (losses) of unconsolidated investees, net of tax

     

    0.4

     

     

     

    0.2

    Consolidated net income

     

    16.8

     

     

     

    52.0

    Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries

     

    (0.6

    )

     

     

    1.1

    Net income attributable to Bruker Corporation

    $

    17.4

     

     

    $

    50.9

    Net income per common share attributable to Bruker Corporation shareholders:

     

     

     

     

    Basic

    $

    0.11

     

     

    $

    0.35

    Diluted

    $

    0.11

     

     

    $

    0.35

    Weighted average common shares outstanding:

     

     

     

     

    Basic

     

    151.6

     

     

     

    145.2

    Diluted

     

    151.9

     

     

     

    145.9

     

    (a) On subsequent pages this is referred to as "Profit before income tax".

    Bruker Corporation

    PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

    (in millions)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Cash flows from operating activities:

     

     

     

     

     

    Consolidated net income

    $

    16.8

     

     

    $

    52.0

     

    Adjustments to reconcile consolidated net income to cash flows from operating activities:

     

     

     

     

     

    Depreciation and amortization

     

    50.4

     

     

     

    34.7

     

    Deferred income taxes

     

    (22.7

    )

     

     

    (2.1

    )

    Other non-cash expenses, net

     

    11.2

     

     

     

    0.6

     

    Changes in operating assets and liabilities, net of acquisitions and divestitures

     

    9.3

     

     

     

    (63.4

    )

    Net cash provided by operating activities

     

    65.0

     

     

     

    21.8

     

     

     

     

     

     

     

    Cash flows from investing activities:

     

     

     

     

     

    Purchases of property, plant and equipment

     

    (26.0

    )

     

     

    (21.4

    )

    Cash paid for acquisitions, net of cash acquired

     

    (1.1

    )

     

     

    (274.5

    )

    Other investing activities, net

     

    1.0

     

     

     

    (8.3

    )

    Net cash used in investing activities

     

    (26.1

    )

     

     

    (304.2

    )

     

     

     

     

     

     

    Cash flows from financing activities:

     

     

     

     

     

    Repayments of revolving lines of credit

     

    (167.9

    )

     

     

    (0.5

    )

    Proceeds from revolving lines of credit

     

    139.9

     

     

     

    268.9

     

    Repayment of long-term debt

     

    (7.7

    )

     

     

    (107.2

    )

    Proceeds from long-term debt

     

    2.9

     

     

     

    —

     

    Payment of dividends to common shareholders

     

    (7.7

    )

     

     

    (7.3

    )

    Repurchase of common stock

     

    (10.0

    )

     

     

    —

     

    Other financing activities, net

     

    (0.7

    )

     

     

    (2.2

    )

    Net cash provided by (used in) financing activities

     

    (51.2

    )

     

     

    151.7

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

    13.3

     

     

     

    (17.6

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    1.0

     

     

     

    (148.3

    )

    Cash, cash equivalents and restricted cash at beginning of period

     

    186.7

     

     

     

    491.6

     

    Cash, cash equivalents and restricted cash at end of period

    $

    187.7

     

     

    $

    343.3

     

    Bruker Corporation

    RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES

    (unaudited and in millions, except per share data)

    The tables below present the GAAP to Non-GAAP reconciliation for the following financial measures: Gross Profit and Gross Profit Margin; Selling, General and Administrative ("SG&A") Expenses; Interest and Other Income (Expense), net; Operating Income and Operating Income Margin; Profit before Income Taxes; Net Income Attributable to Bruker Corporation; Earnings Per Share (Diluted); and Income Tax rate.

     

     

    Gross Profit

     

    Gross Profit Margin

     

    SG&A Expenses

     

    Operating Income

     

    Operating Income Margin

     

    Interest and other income (expense), net

     

    Profit before income tax

     

    Net Income attributable to Bruker Corporation

     

    Diluted net income per common share

     

    Income Tax Rate

    Three Months Ended March 31, 2025:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP

    $

    391.2

     

    48.8

    %

     

    $

    225.4

     

     

    $

    31.8

     

    4.0

    %

     

    $

    (6.7

    )

     

    $

    25.1

     

    $

    17.4

     

     

    $

    0.11

     

     

    34.7

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring costs

     

    2.6

     

    0.3

    %

     

     

    —

     

     

     

    10.2

     

    1.3

    %

     

     

    —

     

     

     

    10.2

     

     

    10.2

     

     

     

    0.07

     

     

    —

     

    Acquisition-related costs

     

    2.3

     

    0.3

    %

     

     

    —

     

     

     

    8.6

     

    1.1

    %

     

     

    —

     

     

     

    8.6

     

     

    8.6

     

     

     

    0.06

     

     

     

    Purchased intangibles amortization

     

    14.0

     

    1.7

    %

     

     

    (13.1

    )

     

     

    27.3

     

    3.4

    %

     

     

    —

     

     

     

    27.3

     

     

    27.3

     

     

     

    0.18

     

     

    —

     

    Acquisition-related litigation charges

     

    —

     

    —

     

     

     

    —

     

     

     

    18.6

     

    2.3

    %

     

     

    —

     

     

     

    18.6

     

     

    18.6

     

     

     

    0.12

     

     

     

    Investments related adjustments

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    2.0

     

     

     

    2.0

     

     

    2.0

     

     

     

    0.01

     

     

    —

     

    Other costs

     

    0.8

     

    0.2

    %

     

     

    —

     

     

     

    5.2

     

    0.6

    %

     

     

    —

     

     

     

    5.2

     

     

    5.2

     

     

     

    0.03

     

     

     

    Tax effect of above Non-GAAP adjustments

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    (18.2

    )

     

     

    (0.11

    )

     

    (0.6

    )%

    Other Discrete Items

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    —

     

     

     

    —

     

     

    (6.4

    )%

    Equity in income (losses) of unconsolidated investees, net of tax

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    (0.4

    )

     

     

    —

     

     

    —

     

    Total Non-GAAP adjustments

     

    19.7

     

    2.5

    %

     

     

    (13.1

    )

     

     

    69.9

     

    8.7

    %

     

     

    2.0

     

     

     

    71.9

     

     

    53.3

     

     

     

    0.36

     

     

    (7.0

    )%

    Non-GAAP

    $

    410.9

     

    51.3

    %

     

    $

    212.3

     

     

    $

    101.7

     

    12.7

    %

     

    $

    (4.7

    )

     

    $

    97.0

     

    $

    70.7

     

     

    $

    0.47

     

     

    27.7

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31, 2024:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP

    $

    352.8

     

    48.9

    %

     

    $

    195.3

     

     

    $

    64.8

     

    9.0

    %

     

    $

    6.8

     

     

    $

    71.6

     

    $

    50.9

     

     

    $

    0.35

     

     

    27.7

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring costs

     

    3.7

     

    0.5

    %

     

     

    —

     

     

     

    7.2

     

    1.0

    %

     

     

    —

     

     

     

    7.2

     

     

    7.2

     

     

     

    0.05

     

     

    —

     

    Acquisition-related costs

     

    3.0

     

    0.4

    %

     

     

    —

     

     

     

    7.1

     

    1.0

    %

     

     

    —

     

     

     

    7.1

     

     

    7.1

     

     

     

    0.05

     

     

    —

     

    Purchased intangibles amortization

     

    7.8

     

    1.1

    %

     

     

    (8.3

    )

     

     

    16.2

     

    2.2

    %

     

     

    —

     

     

     

    16.2

     

     

    16.2

     

     

     

    0.11

     

     

    —

     

    Other costs

     

    2.1

     

    0.3

    %

     

     

    —

     

     

     

    5.4

     

    0.8

    %

     

     

    —

     

     

     

    5.4

     

     

    5.4

     

     

     

    0.04

     

     

    —

     

    Tax effect of above Non-GAAP adjustments

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    (8.9

    )

     

     

    (0.07

    )

     

    (0.6

    )%

    Other Discrete Items

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    —

     

     

     

    —

     

     

    (0.4

    )%

    Equity in income (losses) of unconsolidated investees, net of tax

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

    —

     

     

     

    —

     

     

     

    —

     

     

    (0.2

    )

     

     

    —

     

     

    —

     

    Total Non-GAAP adjustments

     

    16.6

     

    2.3

    %

     

     

    (8.3

    )

     

     

    35.9

     

    5.0

    %

     

     

    —

     

     

     

    35.9

     

     

    26.8

     

     

     

    0.18

     

     

    (1.0

    )%

    Non-GAAP

    $

    369.4

     

    51.2

    %

     

    $

    187.0

     

     

    $

    100.7

     

    14.0

    %

     

    $

    6.8

     

     

    $

    107.5

     

    $

    77.7

     

     

    $

    0.53

     

     

    26.7

    %

    Bruker Corporation

    RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued

    (unaudited and in millions, except per share data)

    The tables below present the GAAP to Non-GAAP reconciliation for Organic revenue, CER currency revenue, and Free Cash Flow:

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    GAAP revenue Total Bruker

    $

    801.4

     

     

    $

    721.7

     

    Non-GAAP adjustments:

     

     

     

     

     

    Acquisitions and divestitures (1)

     

    69.2

     

     

     

    26.3

     

    Effect of changes in foreign currency translation rate (2)

     

    (10.4

    )

     

     

    (1.0

    )

    Non-GAAP Organic revenue Total Bruker

    $

    742.6

     

     

    $

    696.4

     

    GAAP Revenue growth rate

     

    11.0

    %

     

     

    5.3

    %

    Non-GAAP Organic revenue growth rate

     

    2.9

    %

     

     

    1.6

    %

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    GAAP revenue Bruker Scientific Instruments (3)

    $

    744.5

     

     

    $

    651.1

     

    Non-GAAP adjustments:

     

     

     

     

     

    Acquisitions and divestitures (1)

     

    69.2

     

     

     

    26.3

     

    Effect of changes in foreign currency translation rate (2)

     

    (9.2

    )

     

     

    (1.8

    )

    Non-GAAP Organic revenue Bruker Scientific Instruments

    $

    684.5

     

     

    $

    626.6

     

    GAAP Revenue growth rate

     

    14.3

    %

     

     

    3.9

    %

    Non-GAAP Organic revenue growth rate

     

    5.1

    %

     

     

    0.0

    %

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    GAAP revenue BEST, net of Intercompany Eliminations

    $

    56.9

     

     

    $

    70.6

     

    Non-GAAP adjustments:

     

     

     

     

     

    Acquisitions and divestitures (1)

     

    —

     

     

     

    —

     

    Effect of changes in foreign currency translation rate (2)

     

    (1.2

    )

     

     

    0.8

     

    Non-GAAP Organic revenue BEST, net of Intercompany Eliminations

    $

    58.1

     

     

    $

    69.8

     

    GAAP Revenue growth rate

     

    (19.4

    )%

     

     

    20.3

    %

    Non-GAAP Organic revenue growth rate

     

    (17.7

    )%

     

     

    18.9

    %

     

    (1) We define the term acquisitions and divestitures revenue as GAAP revenue from M&A activities excluding the effect of changes in foreign currency translation rates.

    (2) We define the term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions and divestitures.

    (3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31, 2024.

    Bruker Corporation

    RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued

    (unaudited and in millions, except per share data)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    GAAP revenue

    $

    801.4

     

     

    $

    721.7

     

    Non-GAAP adjustments:

     

     

     

     

     

    Effect of changes in foreign currency translation rates

     

    (10.4

    )

     

     

    (1.0

    )

    Non-GAAP CER currency revenue

    $

    811.8

     

     

    $

    722.7

     

    GAAP Revenue growth rate

     

    11.0

    %

     

     

    5.3

    %

    Non-GAAP CER currency revenue growth rate

     

    12.5

    %

     

     

    5.5

    %

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Net cash provided by operating activities

    $

    65.0

     

     

    $

    21.8

     

    Non-GAAP adjustments:

     

     

     

     

     

    Purchases of property, plant and equipment

     

    (26.0

    )

     

     

    (21.4

    )

    Non-GAAP free cash flow (use)

    $

    39.0

     

     

    $

    0.4

     

    Bruker Corporation

    REVENUE

    (unaudited and in millions)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Revenue by Segment:

     

     

     

     

     

    Bruker BioSpin

    $

    207.8

     

     

    $

    182.8

     

    Bruker CALID

     

    280.1

     

     

     

    227.9

     

    Bruker Nano

     

    256.6

     

     

     

    240.4

     

    BSI Revenue Total

     

    744.5

     

     

     

    651.1

     

    BEST

     

    59.3

     

     

     

    73.1

     

    Eliminations

     

    (2.4

    )

     

     

    (2.5

    )

    Total revenue

    $

    801.4

     

     

    $

    721.7

     

     

     

     

     

     

     

    Revenue by End Customer Geography:

     

     

     

     

     

    United States

    $

    217.4

     

     

    $

    194.8

     

    Europe

     

    285.2

     

     

     

    244.9

     

    Asia Pacific

     

    232.6

     

     

     

    222.7

     

    Other

     

    66.2

     

     

     

    59.3

     

    Total revenue

    $

    801.4

     

     

    $

    721.7

     

    Bruker Corporation

    Summary of Reported Revenue Growth Components

    (unaudited and in millions)

    The table below presents a summary of reported revenue growth components for the periods reported for Bruker Corporation, Bruker Scientific Instruments, and BEST net of Intercompany Eliminations.

     

     

     

     

    Variance explained by:

     

     

     

     

     

     

     

    GAAP revenue

    as of prior

    comparable period

     

    Acquisitions

    and divestitures revenue (1)

     

    Organic

    revenue (2)

     

    Effect of changes in foreign currency translation rates

     

    GAAP revenue

    current period

     

    Revenue growth

     

    Organic

    revenue growth

    Total Bruker:

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31, 2025

    $721.7

     

    69.2

     

    20.9

     

    (10.4)

     

    $801.4

     

    11.0%

     

    2.9%

    Three Months Ended March 31, 2024

    $685.3

     

    26.3

     

    11.1

     

    (1.0)

     

    $721.7

     

    5.3%

     

    1.6%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Bruker Scientific Instruments (3):

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31, 2025

    $651.1

     

    69.2

     

    33.4

     

    (9.2)

     

    $744.5

     

    14.3%

     

    5.1%

    Three Months Ended March 31, 2024

    $626.6

     

    26.3

     

    —

     

    (1.8)

     

    $651.1

     

    3.9%

     

    0.0%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    BEST, net of Intercompany Eliminations:

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31, 2025

    $70.6

     

    —

     

    (12.5)

     

    (1.2)

     

    $56.9

     

    (19.4%)

     

    (17.7%)

    Three Months Ended March 31, 2024

    $58.7

     

    —

     

    11.1

     

    0.8

     

    $70.6

     

    20.3%

     

    18.9%

     

    (1) We define the term acquisitions and divestitures revenue as GAAP revenue from M&A activities excluding the effect of changes in foreign currency translation rates.

    (2) We define the term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions and divestitures.

    (3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31, 2024.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507886016/en/

    Joe Kostka

    Director, Investor Relations

    Bruker Corporation

    T: +1 (978) 313-5800

    E: [email protected]

    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    2/14/2024$60.00 → $90.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $BRKR
    Financials

    Live finance-specific insights

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First Quarter 2025 Preliminary Revenue

      Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net

      4/11/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsc

      2/21/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

      Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

      4/4/24 8:11:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker upgraded by Goldman with a new price target

      Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00

      12/5/24 7:35:59 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:23:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      11/19/24 4:07:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Linton William A exercised 10,000 shares at a strike of $24.00, increasing direct ownership by 21% to 58,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      4/24/25 4:15:05 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Francis Laura

      3 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:40:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

      Advancements include CosMx® 2.0 upgrade; CosMx same-slide multiomics; and multiomics capabilities on the nCounter® platform Bruker Corporation (NASDAQ:BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These new advancements build upon the innovations announced at AGBT, including launch of CosMx WTX assay for subcellular spatial imaging of the whole transcriptome, the PaintScape™ platform for visualization of 3D genome architecture and chromosomal structure in single cells, the PowerOMX™ engine for streamlined spatial proteomics analysis on the CellScape™

      4/25/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

      A Compact Benchtop Optofluidic System with Lower Cost of Ownership for Broader Research Accessibility Bruker Corporation (NASDAQ:BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424150192/en/Beacon Discovery – an accessible, compact system for live single-cell functional analysis Building on Bruker's proprietary Opto-Electrical Positioning (OEP) technology and sc

      4/24/25 7:30:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/14/24 1:28:29 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/13/24 6:01:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 11:54:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bruker Corporation

      10-Q - BRUKER CORP (0001109354) (Filer)

      5/7/25 4:04:14 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      5/7/25 7:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Bruker Corporation

      DEF 14A - BRUKER CORP (0001109354) (Filer)

      4/11/25 4:28:51 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials